350 related articles for article (PubMed ID: 34092721)
1. Real World Treatment Practices for Chronic Lymphocytic Leukemia in Japan: An Observational Database Research Study (CLIMBER-DBR).
Takizawa J; Izutsu K; Nagai H; Fukase K; Nakamura M; Jinushi M; Suzumiya J
J Clin Exp Hematop; 2021 Sep; 61(3):126-134. PubMed ID: 34092721
[TBL] [Abstract][Full Text] [Related]
2. Real World Treatment Practices for Mantle Cell Lymphoma in Japan: An Observational Database Research Study (CLIMBER-DBR).
Izutsu K; Suzumiya J; Takizawa J; Fukase K; Nakamura M; Jinushi M; Nagai H
J Clin Exp Hematop; 2021 Sep; 61(3):135-144. PubMed ID: 34092722
[TBL] [Abstract][Full Text] [Related]
3. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
Kabadi SM; Near A; Wada K; Burudpakdee C
Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States.
Kabadi SM; Goyal RK; Nagar SP; Kaye JA; Davis KL
Cancer Med; 2019 Jul; 8(8):3803-3810. PubMed ID: 31144473
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US.
Yang X; Zanardo E; Lejeune D; De Nigris E; Sarpong E; Farooqui M; Laliberté F
Oncologist; 2024 Mar; 29(3):e360-e371. PubMed ID: 38280190
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan.
Tamura K; Sawada H; Izumi Y; Fukuda T; Utsunomiya A; Ikeda S; Uike N; Tsukada J; Kawano F; Shibuya T; Gondo H; Okamura S; Suzumiya J;
Eur J Haematol; 2001 Sep; 67(3):152-7. PubMed ID: 11737247
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology, longitudinal treatment patterns and outcomes of chronic lymphocytic leukemia in Israel.
Weil C; Chodick G; Shalev V; Kan I; Afik R; Cohen R; Sail K; Herishanu Y
Leuk Lymphoma; 2021 May; 62(5):1136-1145. PubMed ID: 33305641
[TBL] [Abstract][Full Text] [Related]
8. Real-world clinical experience in the Connect
Mato A; Nabhan C; Kay NE; Weiss MA; Lamanna N; Kipps TJ; Grinblatt DL; Flinn IW; Kozloff MF; Flowers CR; Farber CM; Kiselev P; Swern AS; Sullivan K; Flick ED; Sharman JP
Br J Haematol; 2016 Dec; 175(5):892-903. PubMed ID: 27861736
[TBL] [Abstract][Full Text] [Related]
9. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
Smolej L; Brychtová Y; Cmunt E; Doubek M; Špaček M; Belada D; Šimkovič M; Stejskal L; Zygulová I; Urbanová R; Brejcha M; Zuchnická J; Móciková H; Kozák T;
Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study.
Maruyama D; Wang C; Tanizawa Y; Cai Z; Huang Y; Tajimi M; Kusumoto S
J Clin Exp Hematop; 2023; 63(4):219-229. PubMed ID: 38148012
[TBL] [Abstract][Full Text] [Related]
11. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.
Goyal RK; Nagar SP; Kabadi SM; Le H; Davis KL; Kaye JA
Cancer Med; 2021 Apr; 10(8):2690-2702. PubMed ID: 33734606
[TBL] [Abstract][Full Text] [Related]
12. Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.
Nabhan C; Mato A; Flowers CR; Grinblatt DL; Lamanna N; Weiss MA; Davids MS; Swern AS; Bhushan S; Sullivan K; Flick ED; Kiselev P; Sharman JP
BMC Cancer; 2017 Mar; 17(1):198. PubMed ID: 28302090
[TBL] [Abstract][Full Text] [Related]
13. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Salles G; Bachy E; Smolej L; Simkovic M; Baseggio L; Panovska A; Besson H; Healy N; Garside J; Iraqi W; Diels J; Pick-Lauer C; Spacek M; Urbanova R; Lysak D; Hermans R; Lundbom J; Callet-Bauchu E; Doubek M
Ann Hematol; 2019 Dec; 98(12):2749-2760. PubMed ID: 31745601
[TBL] [Abstract][Full Text] [Related]
14. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
16. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Huang SJ; Gerrie AS; Young S; Tucker T; Bruyere H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn L; Toze CL
Leuk Res; 2020 Apr; 91():106335. PubMed ID: 32114372
[TBL] [Abstract][Full Text] [Related]
17. Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.
Lee LJ; Toze CL; Huang SJT; Gillan TL; Connors JM; Sehn LH; Bruyere H; Leitch H; Ramadan KM; Gerrie AS
Leuk Lymphoma; 2018 Jun; 59(6):1356-1363. PubMed ID: 29032719
[TBL] [Abstract][Full Text] [Related]
18. Invasive Fungal Disease in Patients with Chronic Lymphocytic Leukemia in Japan: A Retrospective Database Study.
Yasu T; Sakurai K; Akazawa M
Curr Oncol; 2022 May; 29(5):3242-3251. PubMed ID: 35621654
[TBL] [Abstract][Full Text] [Related]
19. A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Owen C; Bence-Bruckler I; Chamakhi I; Toze C; Assaily W; Christofides A; Robinson S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):303-13. PubMed ID: 25937158
[TBL] [Abstract][Full Text] [Related]
20. Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.
Zoellner AK; Höhler T; Fries S; Böhme A; Kiewe P; Kellermann L; Dreyling M
Ann Hematol; 2016 May; 95(6):853-61. PubMed ID: 27021305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]